Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Transferrin modified graphene oxide for glioma-targeted drug delivery: in vitro and in vivo evaluations.

Authors
  • Liu, Guodong
  • Shen, He
  • Mao, Jinning
  • Zhang, Liming
  • Jiang, Zhen
  • Sun, Tao
  • Lan, Qing
  • Zhang, Zhijun
Type
Published Article
Journal
ACS Applied Materials & Interfaces
Publisher
American Chemical Society
Publication Date
Aug 14, 2013
Volume
5
Issue
15
Pages
6909–6914
Identifiers
DOI: 10.1021/am402128s
PMID: 23883622
Source
Medline
License
Unknown

Abstract

Transferrin (Tf), an iron-transporting serum glycoprotein that binds to receptors overexpressed at the surface of glioma cells, was chosen as the ligand to develop Tf-conjugated PEGylated nanoscaled graphene oxide (GO) for loading and glioma targeting delivery of anticancer drug doxorubicin (Dox) (Tf-PEG-GO-Dox). Tf-GO with lateral dimensions of 100-400 nm exhibited a Dox loading ratio up to 115.4%. Compared with Dox-loaded PEGylated GO (PEG-GO-Dox) and free Dox, Tf-PEG-GO-Dox displayed greater intracellular delivery efficiency and stronger cytotoxicity against C6 glioma cells. A competition test showed that Tf was essential to glioma targeting in vitro. The HPLC assay for Dox concentration in tumor tissue and contrapart tissue of the brain demonstrated that Tf-PEG-GO-Dox could deliver more Dox into tumor in vivo. The life span of tumor bearing rats after the administration of Tf-PEG-GO-Dox was extended significantly compared to the rats treated with saline, Dox, and PEG-GO-Dox. In conclusion, we developed Tf-PEG-GO-Dox which exhibited significantly improved therapeutic efficacy for glioma both in vitro and in vivo.

Report this publication

Statistics

Seen <100 times